Skip to main content
Log in

Fighting cancer with nanoparticle medicines―The nanoscale matters

  • Technical Features
  • Published:
MRS Bulletin Aims and scope Submit manuscript

Abstract

Papyrus writings from 1600–1500 BC describe cancer and the attempts at treatment. Centuries later, cancer remains a devastating disease. Given the long history of difficulties in developing cancer therapies, why is there excitement about nanoparticle medicine (nanomedicines) for fighting cancer? This article describes the current understanding of why these engineered, nano-sized medicines, which are highly multifunctional chemical systems, have the potential to provide revolutionary ways to treat cancer. This point is illustrated by physical insights at the nanoscale that allow for the development of nanoparticles that can function in both animals and humans. The human data show how we have translated two independent nanoparticle cancer therapeutics from laboratory curiosities to experimental therapeutics in human clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. A. Jemal, R. Siegel, J. Xu, E. Ward, CA-Cancer J. Clin. 60, 277 (2010).

    Article  Google Scholar 

  2. Data from the World Bank, www.worldbank.org.

  3. T. O’Callaghan, Nature 471 (7339), S2 (2011).

    Article  CAS  Google Scholar 

  4. M.R. Dreher, W. Liu, C.R. Michelich, M.W. Dewhirst, F. Yuan, A. Chilkoti J. Natl. Cancer Inst. 98 (5), 335 (2006).

  5. M.E. Davis, Mol. Pharmacol. 6 (3), 659 (2009).

  6. L. Lacenda, M.A. Herrero, K. Venner, A. Bianco, M. Prato, K. Kostarelos, Small 4 (8), 1130 (2008).

  7. A. Ruggiero, C.H. Villa, E. Bander, D.A. Rey, M. Bergkvist, C.A. Batt, K. Manova-Todorova, W.M. Deen, D.A. Scheinberg, M.R. McDevitt, PNAS 107 (27), 12369 (2010).

  8. J.A.J. Fitzpatrick, S.K. Andreko, L.A. Ernst, A.S. Waggoner, B. Ballou, M.P. Bruchez, Nano. Lett. 9 (7), 2736 (2009).

  9. H. Cabral, Y. Matsumoto, K. Mizuno, Q. Chen, M. Murakami, M. Kimura, Y. Terada, M.R. Kano, K. Miyazono, M. Uesaka, N. Nishiyama, K. Kataoka, Nat. Nanotechnol. 6, 815 (2011).

  10. S.R. Popielarski, S. Hu-Lieskovan, S.W. French, T.J. Triche, M.E. Davis, Bioconjugate Chem. 16 (5), 1071 (2005).

  11. W. Jiang, B.Y.S. Kim, J.T. Rutka, W.C.W. Chan, Nat. Nanotechnol. 3 (3), 145 (2008).

  12. S. Mishra, P. Webster, M.E. Davis, Eur. J. Cell Biol. 83, 1 (2004).

  13. A.Z. Fire, “Gene silencing by double stranded RNA” (Nobel Lecture, December 8, 2006), p. 224; www.nobelprize.org/nobel_prizes/medicine/laureates/2006/fire_lecture.pdf.

  14. M.E. Davis, J.E. Zuckerman, C.H.J. Choi, D. Seligson, A. Tolcher, C.A. Alabi Y. Yen, J.D. Heidel, A. Ribas, Nature 464, 1067 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark E. Davis.

Additional information

The following article is an edited transcript of the Fred Kavli Distinguished Lecture in Nanoscience presented by Mark E. Davis, on November 27, 2011, at the 2011 Materials Research Society Fall Meeting in Boston. The Lectureship is supported by the Kavli Foundation, which supports scientific research, honors scientific achievement, and promotes public understanding of scientists and their work. A video of the presentation can be viewed at www.mrs.org/f11-kavli-video.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davis, M.E. Fighting cancer with nanoparticle medicines―The nanoscale matters. MRS Bulletin 37, 828–835 (2012). https://doi.org/10.1557/mrs.2012.202

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1557/mrs.2012.202

Navigation